Ascendis Pharma A/S
ASND
172 hedge funds and large institutions have $7.85B invested in Ascendis Pharma A/S in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 50 reducing their positions, and 27 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 50
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
4% more funds holding
Funds holding: 166 → 172 (+6)
0.3% less ownership
Funds ownership: 102.85% → 102.55% (-0.3%)
15% less capital invested
Capital invested by funds: $9.25B → $7.85B (-$1.39B)
21% less call options, than puts
Call options by funds: $9.62M | Put options by funds: $12.2M
Top Buyers
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$78.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$36.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$33.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$26.8M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$23.1M |
Top Sellers
ASND Hedge Fund Activity: Q4 2021 in Review
172 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2021, worth a combined $7.85B — down 15% from $9.25B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ASND positions and 27 closed out — a net gain of 7 holders — while 67 added to existing stakes and 50 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $78.8M. The largest seller was Lone Pine Capital, exiting entirely with an estimated $229M sold.
- 172 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2021, up from 166 in Q3 2021.
- Funds reported $7.85B of Ascendis Pharma A/S stock for Q4 2021, down 15% quarter-over-quarter.
- 34 funds opened new Ascendis Pharma A/S positions in Q4 2021 and 27 closed out, a net change of +7 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2021 was Westfield Capital Management, an estimated $78.8M added.
- The largest Ascendis Pharma A/S seller in Q4 2021 was Lone Pine Capital, an estimated $229M sold.
Based on aggregated 13F filings for Q4 2021.